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A B S T R A C T
Although previously reported, the existence of a neurofibromatosis (NF)-associated diffuse lung disease (DLD)
still lacks solid evidence. We report a case of a 68-year-old non-smoking female with NF1, pre-capillary pul-
monary hypertension (PH) and an interstitial lung pattern. Initial findings included progressive dyspnea, hy-
poxemia and sparse centrilobular ground-glass micronodules on high-resolution computed tomography (HRCT).
Further study demonstrated a severe defect in diffusing capacity for carbon monoxide (DLCO), macrophages on
bronchoalveolar lavage and pre-capillary PH on right cardiac catheterization. Surgical biopsy revealed macro-
phage accumulation along bronchovascular bundles and alveolar spaces and type II pneumocytes hyperplasia.
Given the absence of environmental exposure or new drugs, a NF-DLD was hypothesized. Pre-capillary PH was
disproportionate to interstitial findings, so it was attributed to a NF1-vasculopathy. Treatment with triple se-
quential combined therapy was unsuccessful culminating in death 18 months later. This case adds HRCT and
anatomopathological data suggesting NF-DLD as a distinct manifestation of the disease.
1. Introduction
Neurofibromatosis type 1 (NF1) is a relatively common single-gene
disorder, with an estimated incidence of 1 in 2500–3000 individuals
[1].
Cutaneous, musculoskeletal and neurological involvement is fre-
quent [1,2]. In the spectrum of thoracic manifestations [3], abnorm-
alities in pulmonary vasculature and parenchyma are rarely seen [2,3].
For several decades there have been reports of NF-DLD [4–11]
however that association still lacks robust evidence. To date, more than
60 cases have been described [4–13], but few included HRCT scans or
lung biopsy [5,10–13]. HRCT findings reported in NF include upper
lobe predominant cysts and bullae, ground-glass opacifications and
basilar reticular abnormalities. Histological data is even poorer, re-
garding the paucity of anatomopathological reports in published series
[5,10–12].
Pulmonary hypertension (PH) is another rare NF1 manifestation,
resulting from an underlying vasculopathy whose mechanisms are not
fully understood [14,15].
The authors present a rare case of a non-smoking female with NF1
presenting a pre-capillary PH and centrilobular ground-glass micro-
nodules in HRCT, in which histological documentation of DLD was
obtained. The actual existence of an NF-DLD is subject of debate in the
scientific community. We believe that the presented case provides ad-
ditional data favoring the existence of NF-DLD as a distinct clinical
entity.
2. Case report
A 68-year-old female presented with progressive exertional dyspnea
for a year. She worked as a quality controller in the denim industry.
There was history of dyslipidemia, multinodular goiter and osteo-
porosis. Chronic medication was Pytavastatine, Alendronic Acid and
Colecalciferol.
There was no smoking or other known environmental exposure.
Physical examination showed one cafe au lait spot on an ankle and
four on the trunk, multiple cutaneous neurofibromas and axillary
freckles (Fig. 1).
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Cardiopulmonary auscultation was normal. Arterial blood gas ana-
lysis revealed hypoxemia (pa02=55mmHg) and CT-angiography had
no signs of pulmonary embolism but indicated a sparse ground-glass
centrilobular micronodular infiltrate. Initial transthoracic echocardio-
gram showed preserved global systolic function and minimal tricuspid
insufficiency, with pulmonary artery systolic pressure (PASP) of
32mmHg; autoimmune study was normal and HIV serology was ne-
gative.
The subsequent investigation included respiratory functional tests
that revealed reduced DLCO (2.15 mmol/min/kPa, 33.5%) and 6MWT
with O2 supplementation at 2L/min that showed a significant desa-
turation (walked distance: 240m/61%, desaturation from 97 to 81%).
HRCT revealed patchy areas of centrilobular ground-glass micro-
nodules (Fig. 2).
Bronchoalveolar lavage (BAL) citoimunologic study revealed in-
creased monocytes/macrophages (97%). A transthoracic lung biopsy
was also performed but it didn't allow a definitive diagnosis.
Concomitantly, the presence of cafe au lait spots, axillary freckles
and cutaneous neurofibromas lead to the suspicion of NF1. Further
investigation revealed multiple bilateral Lisch nodules. The conjugation
of established well-defined clinical criteria (two or more Lisch nodules,
two or more neurofibromas and axillary freckling) allowed a definitive
diagnosis of NF1, which was complemented by genetic study (with
identification of one of the known NF1-related somatic mutations -
exon53:c.7846C > T).
In the meantime, there was a progressive clinical worsening with
development of cor pulmonale. Right heart catheterization was per-
formed and confirmed pre-capillary PH (mean PASP: 41mmHg; pul-
monary wedge pressure: 9 mmHg; pulmonary vascular resistance
(PVR): 10.73UWood; cardiac index (CI)= 2,39L/min/m2). Pre-capil-
lary PH could fit in group 5, secondary to NF, but at this time there were
doubts about the presence of a diffuse lung disease (DLD), so surgical
lung biopsy was requested.
The material obtained was reviewed in the Pathology Department of
Royal Brompton Hospital in London. There was marked thickening of
the intima of arteries and some arterioles as a manifestation of vascular
disease. It was also visible an accumulation of macrophages along
bronchovascular bundles but also at alveolar spaces and hyperplasia of
type II pneumocytes (Fig. 3).
With regard to interstitial findings, the diagnosis of respiratory
bronchiolitis (RB-ILD) was considered, however there was no smoke
exposure history. As in other previous publications, the presence of
interstitial abnormalities in the context of NF1 was hypothesized.
The patient was diagnosed as having a DLD with a mild radiologic
appearance, disproportionate to pulmonary vascular disease so that
pre-capillary PH was interpreted in the context of NF.
She was referred to a PH treatment center in class III of New York
Heart Association (NYHA). The patient began Iloprost in January 2014;
Bosentan and Sildenafil were added a month later and Iloprost was
changed to Epoprostenol IV 6 months later. There was no response to
triple therapy and the patient experimented progressive deterioration
culminating in death 18 months after treatment beginning.
3. Discussion
NF1 is a common neurogenetic disease of autosomal dominant in-
heritance affecting ectodermal and mesodermal tissues [1,10]. Half of
the cases are familiar and the other half result from spontaneous mu-
tations. The disease is caused by a mutation in a gene on the long arm of
chromosome 17 (NF1 gene) encoding Neurofibromin, a GTPase-acti-
vator protein that produces a downregulation of proto-oncogenes. As a
result, there is a disproportional cell proliferation leading to an in-
creased risk of neoplasms [2].
NF diagnosis is based on well-defined clinical criteria, requiring the
fulfillment of at least two items in order to assert the diagnosis [1].
Although the mutation in NF1 gene has complete penetrance, the
disease itself is highly variable in its clinical manifestations and degrees
of severity [1,16].
Fig. 1. Café au lait spot (left), cutaneous neurofibroma (center) and axillary freckles (right).
Fig. 2. Chest CT (axial reconstruction, pulmonary window) revealing patchy areas of centrilobular ground-glass micronodules.
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Vasculopathy is a recognized but rare expression of the disease with
an estimated prevalence of 0.4–6.4% [17]. Characteristically there is a
proliferation of intima and media layers usually involving renal, me-
senteric and aortic vessels [14,17]. The involvement of pulmonary ar-
terial beds with associated pulmonary hypertension is unusual in NF1
[14,15,17].
In 2011, Montani et al. published a report of 8 patients with NF1-
related PH [18]. Like in our case, PH occurred late in the course of the
disease. Dyspnea and right heart failure signs were the initial findings.
At diagnosis, patients had severe hemodynamic impairment with low CI
(median 2.3 L/min/m2) and elevated indexed PVR (median
15.1 mmHg/L/min/m2). All patients were in NYHA III with severe ex-
ercise limitation (median 6-min walked distance: 180 m).
PH late diagnosis in NF1 patients is probably related to the indolent
nature of symptoms and brings into question the possible benefit of a
systematic echocardiographic evaluation of patients with an established
diagnosis of NF. However to date this strategy is still not recommended
because of the very low incidence of PH in NF1 patients [15].
The available treatments for PH in NF have been showing dis-
couraging results. An aggressive therapeutic approach similar to group
1 PH, based in a phosphodiesterase-5 inhibitor and an endothelin re-
ceptor antagonist, is currently advocated [18,19]. Usually there is a
progressive course with development of cor pulmonale and progression
to terminal right cardiac failure [15,20].
In addition to vascular findings, interstitial abnormalities have been
also reported in NF1-related PH patients [4-14,20].
Considering again the sample of 8 N1-PH patients analysed by
Montani [18], 5 had also interstitial findings (mainly lung cysts). Like
in our case, in some of them the exuberance of vascular disease was
disproportionate when compared to pulmonary involvement. There-
fore, in our case, considering the subtlety of interstitial findings, PH was
thought to belong more probably to group 5 than to group 3.
Since the last 50 years, the hypothesis of a NF1-related interstitial
disease has aroused interest in the scientific community [4–13]. In fact,
since then and even nowadays, there has been some divergence be-
tween the published studies.
Ryu et al. studied 156 patients with NF with chest radiography and
found evidence of interstitial involvement in only 3 patients (1.9%).
Interstitial findings (cysts, reticular opacities and ground-glass in-
filtrates) were attributed to other known conditions of the patients,
refusing the existence of a characteristic interstitial pattern in NF1 [11].
However, in this study, there was no evaluation with HRCT or lung
biopsy.
Tobacco smoke has been suggested as a potential confounding
factor since the reported bubbles and ground-glass opacities may occur
in smoking emphysema and RB-ILD and not secondarily to NF [21]. In
this regard, some studies also hypothesize that NF1 can potentially
increase lung susceptibility to smoke injury [21,22].
Zamora et al. reviewed 64 literature reports of DLD in patients with
NF1. The mean age of patients was 50 years and 69% were male. HRCT
was performed in only 8 patients and revealed the presence of ground-
glass opacities (37%), bibasilar reticular opacities (50%), bubbles
(50%) and cysts (25%). However the information on smoking history
was only available in 16 patients and only four were non-smokers (one
evaluated with HRCT) [10].
In 2011 Oikonomou et al. evaluated 6 non-smoking NF1 patients
with HRCT. Small thin-walled cysts not associated with emphysema
and micronodular ground-glass infiltrates were observed in all patients.
Despite the absence of histological support, it was stated that the
changes described in this and other related studies were not associated
with smoking and may constitute specific manifestations of NF1 [22].
One year later, Nardecchia et al. reported another case of a 16-year old
non-smoker NF1 patient who presented bilateral apical lung bullae. In
this case, surgical lung biopsy was performed, revealing emphysema-
tous abnormalities [23].
Solid data about histological features in these patients is lacking,
preventing the ascertainment of a potential “NF1 pattern”. In one of
Montani's NF1-PH patients, the pathological assessment of lung tissue
revealed, as in our case, marked intimal hyperplasia in arterial beds and
numerous macrophages and giant cells within alveolar spaces.
However, those interstitial findings could also be related to the patient
previous smoking habits [18].
In this case we believe that pulmonary lung biopsy strongly suggests
the presence of a DLD with accumulation of macrophages in cen-
trilobular regions in a patient with no environmental exposure.
The pertinence of this report seems to us to go beyond its rarity, in
that it allows to reflect on two controversial manifestations of NF1:
pulmonary hypertension, whose mechanisms still need further research
in order to find an effective therapeutic target, and DLD, whose ex-
istence as a NF1-related entity has been discussed for decades and still
lacks a formal extended investigation supported by all the current di-
agnostic tools.
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